The Filing Desk

Eton Pharmaceuticals vs Zevra Therapeutics

Eton Pharmaceuticals ETON · Zevra Therapeutics ZVRA · Pharmaceuticals

Zevra Therapeutics reported revenue of $106 million in fiscal 2025, 1.3 times Eton Pharmaceuticals' $80 million in fiscal 2025. Eton Pharmaceuticals' revenue grew 104.9% in its latest year, and Zevra Therapeutics' grew 350.9%. Eton Pharmaceuticals had an operating margin of -1.1%, against -59.1% at Zevra Therapeutics. Free cash flow was $10 million at Eton Pharmaceuticals and −$2 million at Zevra Therapeutics.

Side by side

Eton PharmaceuticalsZevra Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$80M$106M
Revenue growth104.9%350.9%
Revenue growth a year, last 5 years—51.6%
Gross margin53.5%—
Operating margin−1.1%−59.1%
Net margin−5.8%78.2%
Free cash flow$10M−$2M
Free cash flow margin12.8%−2.3%
Return on capital−1.9%−218.8%
Net debt to EBITDA1.4x—
Dividends and buybacks$0M$0M
Change in diluted share count3.9%23.8%
Last close$63.93$9.08
P/E at the last close—7.6×
Insider trades, last 12 monthssold $25.2 million—
Piotroski F-score4 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Eton PharmaceuticalsZevra Therapeutics
Operating margin
Percent of revenue
Eton PharmaceuticalsZevra Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Eton PharmaceuticalsZevra Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Eton Pharmaceuticals and Zevra Therapeutics pages.